Natural Biogenex gets approval under PLI SchemeIllustrative image – not actual.
Natural Biogenex, a wholly-owned subsidiary of Natural Capsules, has been accorded approval to manufacture three bulk drugs under Production Linked Incentive (PLI) Scheme. 
 
The three bulk drugs approved are Betamethasone with a committed production capacity of 12 million tonne at an investment of Rs 31.43 crore, Dexamethasone with a capacity of 10 million tonne for an investment of Rs 26.19 crore and Prednisolone with a capacity of 15 million tonne for an investment of Rs 39.29 crore. 
 
Apart from this, the companies that received approval were Symbiotec Pharmalab for Prednisolone with a capacity of 15 million tonne at an investment of Rs five crore, Macleods Pharmaceutical for Rifampicin of 200 million tonne and investment Rs 198.36 crore, Optimus Drugs and Sudarshan Pharma for Vitamin B1 with a capacity of 200 million tonne each. 
 
Also, nod was given to Sadhana Nitro Chem for Para amino phenol with a capacity of 36,000 tonne with a committed investment of Rs 197.27 crore, Saraca Laboratories for 1,1 Cyclohexane Diacetic Acid with a capacity of 3,000 tonne with an investment of Rs 50 crore, Emmennar Pharmaj and Hindys Lab  for 1,1 Cyclohexane Diacetic Acid with a capacity of 1,500 tonne and 3,000 tonne. 
 
The setting up of these plants will lead to a total committed investment of Rs 862.01 crore by the companies and employment generation of around 1,763. 
 
With this, a total of 19 applications with committed investment of Rs 4,623.01 crore have been approved by the government. 
 
The commercial production is projected to commence from 1 April 2023 onwards and the disbursal of production-linked incentive by the government over the six years period will be up to a maximum of Rs 4,870 crore.
← All latest storiesBack to top →